NCT02015819View on ClinicalTrials.gov

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 7, 2014

Primary Completion Date

October 7, 2017

Study Completion Date

October 7, 2017

Conditions

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorAnaplastic Oligoastrocytoma

Interventions

BIOLOGICAL

E. coli CD-expressing genetically modified neural stem cells

Given intracranially

DRUG

flucytosine

Given orally

DRUG

leucovorin calcium

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | Biotech Hunter | Biotech Hunter